CAS No.: 895519-90-1
Flumatinib Catalog No. CSN18538
Synonyms: HHGV678
Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT02204644 CML, CML-CP,MMR,TKI Phase 3 Completed - China, Tianjin ... more >> Hospital of Blood Diseases, Chinese Academy of Medical Sciences Tianjin, Tianjin, China, 300020 Collapse << NCT01503502 Myelogenous Leukemia, Chronic Phase 2 Unknown December 2014 China, Beijing ... more >> Peking University People's Hospital Beijing, Beijing, China, 100044 China, Hubei Union Hospital Tongji Medical College Huazhong University of Science and technology Wuhan, Hubei, China, 430022 China, Jiangsu The First Rffiurted Hospital of Soochow University Suzhou, Jiangsu, China, 215006 China, Shanghai Ruijin Hospital Shanghai, Shanghai, China, 200025 China, Tianjin Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin, Tianjin, China, 300020 Collapse << NCT02511340 Chronic Myelogenous Leukemia Phase 2 Unknown December 2015 China, Hubei ... more >> Union Hospital Tongji Medical College Huazhong University of Science and technology Wuhan, Hubei, China, 430022 Collapse << - 参考文献
- [1] Zhao J, Quan H, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
- [2] Luo H, Quan H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib esistance. Leukemia. 2010 Oct;24(10):1807-9
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 895519-90-1 | 储存条件 |
|
|
| 分子式 | C29H29F3N8O | 运输 | 蓝冰 | |
| 分子量 | 562.59 | 别名 | HHGV678 |
